Department of Immunology and Microbiology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Int J Mol Sci. 2019 Jul 2;20(13):3260. doi: 10.3390/ijms20133260.
In recent decades, the elderly population has been rapidly increasing in many countries. Such patients are susceptible to Gram-negative septic shock, namely endotoxin shock. Mortality due to endotoxin shock remains high despite recent advances in medical care. The generalized Shwartzman reaction is well recognized as an experimental endotoxin shock. Aged mice are similarly susceptible to the generalized Shwartzman reaction and show an increased mortality accompanied by the enhanced production of tumor necrosis factor (TNF). Consistent with the findings in the murine model, the in vitro Shwartzman reaction-like response is also age-dependently augmented in human peripheral blood mononuclear cells, as assessed by enhanced TNF production. Interestingly, age-dependently increased innate lymphocytes with T cell receptor-that intermediate expression, such as that of CD8CD122T cells in mice and CD57T cells in humans, may collaborate with macrophages and induce the exacerbation of the Shwartzman reaction in elderly individuals. However, endotoxin tolerance in mice, which resembles a mirror phenomenon of the generalized Shwartzman reaction, drastically reduces the TNF production of macrophages while strongly activating their bactericidal activity in infection. Importantly, this effect can be induced in aged mice. The safe induction of endotoxin tolerance may be a potential therapeutic strategy for refractory septic shock in elderly patients.
近几十年来,许多国家的老年人口迅速增加。此类患者易发生革兰氏阴性菌败血症性休克,即内毒素性休克。尽管医疗保健技术最近取得了进步,但内毒素性休克导致的死亡率仍然很高。全身性施瓦茨曼反应被公认为一种实验性内毒素性休克。年老的小鼠也容易发生全身性施瓦茨曼反应,并表现出死亡率增加,同时肿瘤坏死因子 (TNF) 的产生增加。与在小鼠模型中的发现一致,通过增强 TNF 的产生,体外施瓦茨曼反应样反应也随年龄依赖性增强,如人外周血单核细胞中。有趣的是,与年龄相关的具有 T 细胞受体-中等表达的先天淋巴细胞增加,例如小鼠中的 CD8CD122T 细胞和人类中的 CD57T 细胞,可能与巨噬细胞协同作用并诱导老年人施瓦茨曼反应的恶化。然而,类似于全身性施瓦茨曼反应的内毒素耐受在小鼠中,尽管强烈激活了其在感染中的杀菌活性,但大大降低了巨噬细胞的 TNF 产生。重要的是,这种效应可以在年老的小鼠中诱导。安全诱导内毒素耐受可能是老年败血症性休克患者难治性休克的一种潜在治疗策略。